ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

CORDARONE
CHF and arrhythmias
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

CORDARONE Rx

Generic Name and Formulations:
Amiodarone HCl 200mg; scored tabs.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for CORDARONE:

Documented, life-threatening recurrent ventricular fibrillation or hemodynamically unstable ventricular tachycardia.

Adult:

Give consistently with regard to meals. Loading dose (initiate in hospital with cardiac monitoring): 800–1600mg/day in divided doses with meals for 1–3 weeks. After control achieved, 600–800mg/day for 1 month then reduce to maintenance dose, usually 400mg/day.

Children:

Not established.

Contraindications:

Cardiogenic shock. Marked sinus bradycardia. 2nd- or 3rd-degree AV block. Bradycardia with syncope unless paced.

Warnings/Precautions:

Be experienced with the treatment and monitoring of life-threatening arrhythmias before prescribing this medication. Correct potassium, magnesium and calcium deficiencies prior to initiation. Monitor for pulmonary and liver toxicity; reduce dose or discontinue if either occurs. Perform baseline pulmonary function tests at initiation, then every 3–6 months. Do liver function tests regularly. Surgery. Monitor thyroid function and signs of thyrotoxicosis. Assess implantable cardiac devices. Do regular ophthalmic exams. Withdraw cautiously. Elderly. Neonates (teratogenic effects). Pregnancy, nursing mothers: not recommended.

Interactions:

Interactions may persist months after discontinuing. Symptomatic bradycardia when concomitant with ledipasvir/sofosbuvir or with sofosbuvir plus simeprevir; monitor heart rate when starting antiviral treatment. Potentiates antiarrhythmics (eg, quinidine, procainamide, flecainide; reduce their doses by ⅓ to ½), cyclosporine, digoxin (reduce digoxin dose by ½ or discontinue), oral anticoagulants (reduce anticoagulant dose by ⅓ to ½ and monitor PT), dabigatran, fentanyl, phenytoin, lidocaine, dextromethorphan. Myopathy with statins metabolized by CYP3A4; limit simvastatin dose to 20mg daily or lovastatin dose to 40mg daily. Potentiated by protease inhibitors, loratadine, cimetidine, trazodone, grapefruit juice. Exacerbation of arrhythmias with antiarrhythmics. Additive bradycardia, sinus arrest, and AV block with β-blockers, digoxin, verapamil, diltiazem, ivabradine, clonidine; monitor heart rate. QTc prolongation with Class I and III antiarrhythmics, lithium, phenothiazines, tricyclics, quinolones, macrolides, IV pentamidine, azole antifungals. Antagonized by rifampin, St. John's wort, cholestyramine. May alter results of thyroid function tests. See full labeling.

Pharmacological Class:

Class III antiarrhythmic.

Adverse Reactions:

Nausea, vomiting, alveolitis, pulmonary inflammation or fibrosis, post-op adult respiratory distress syndrome, exacerbation of arrhythmias, heart block or failure, sinus bradycardia, hepatotoxicity, corneal deposits, optic neuropathy/neuritis (reevaluate if occurs), photosensitivity, skin pigmentation, thyroid disorders, malaise, fatigue, peripheral neuropathy, constipation, anorexia.

Generic Availability:

YES

How Supplied:

Tabs—60

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs